2022
Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2022, 175: 479-489. PMID: 35099992, PMCID: PMC9087297, DOI: 10.7326/m21-1548.Peer-Reviewed Original ResearchConceptsCAB-LAHIV preexposure prophylaxisCost-effectiveness analysisPreexposure prophylaxisHigh riskNational InstituteIncremental cost-effectiveness ratioCost-effectiveness ratioBase-case analysisHealth care systemEunice KennedyInjectable cabotegravirPrEP retentionOral PrEPHIV PrEPHIV incidenceBlood InstituteDisoproxil fumarateNational HeartChild healthSide effectsTransgender womenInfectious diseasesPrEPQALY
2018
The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, Walensky RP, Freedberg KA. The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India. Journal Of The International AIDS Society 2018, 21: e25085. PMID: 29603882, PMCID: PMC5878415, DOI: 10.1002/jia2.25085.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careAntiretroviral therapyTenofovir disoproxil fumarateHIV infectionRecent guidelinesFirst-line antiretroviral therapyFirst-line HIV treatmentLifetime incremental cost-effectiveness ratioART-naive patientsDolutegravir-based regimenDTG-based regimenFirst-line treatmentClinical trial dataCost-effectiveness ratioLifetime care costsInitial therapyVirologic suppressionCD4 countHIV diseaseRegimen costsDisoproxil fumarateHIV treatmentAIDS complicationsCare costs
2015
The Epi-TAF for Tenofovir Disoproxil Fumarate?
Walensky RP, Horn TH, Paltiel AD. The Epi-TAF for Tenofovir Disoproxil Fumarate? Clinical Infectious Diseases 2015, 62: 915-918. PMID: 26658300, DOI: 10.1093/cid/civ1000.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateAverage wholesale priceDisoproxil fumarateBone mineral density lossHIV treatment regimenTenofovir/lamivudineImproved toxicity profileHuman immunodeficiency virusMineral density lossAntiretroviral therapyRenal injuryTenofovir alafenamideTreatment regimenImmunodeficiency virusEqual efficacyToxicity profileCost-effectiveness methodsDensity lossUS residentsAlafenamideRegimenLamivudineTherapyInjuryFumarate